EDIT
Price
$2.38Alerts
Change
-$0.13 (-5.18%)
Updated
Nov 11 closing price
Capitalization
394.7M
105 days until earnings call
Intraday BUY SELL Signals
SGMT
Price
$11.41Alerts
Change
+$0.52 (+4.78%)
Updated
Nov 11 closing price
Capitalization
612.26M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs SGMT

EDIT vs SGMT Comparison Chart in %
View a ticker or compare two or three
VS
EDIT vs. SGMT commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongBuy and SGMT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EDIT with price predictions
Nov 11, 2026

Aroon Indicator for EDIT shows an upward move is likely

EDIT's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 128 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for SGMT with price predictions
Nov 11, 2026

SGMT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SGMT turned positive on October 20, 2026. Looking at past instances where SGMT's MACD turned positive, the stock continued to rise in 28 of 31 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SGMT's RSI Oscillator exited the oversold zone, 14 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SGMT as a result. In 47 of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

SGMT moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SGMT crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where SGMT advanced for three days, in 155 of 182 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 108 of 119 cases where SGMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SGMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

SGMT broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.390) is normal, around the industry mean (3.498). P/E Ratio (-7.817) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (75.758) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. SGMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SGMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDIT: Fundamental Ratings
EDIT
OUTLOOK RATING
1..100
73
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
71
P/E GROWTH RATING
1..100
30
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EDITSGMT
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 1 day ago
85%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (EDIT: $2.38 vs. SGMT: $11.41)
Brand notoriety: EDIT and SGMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 73% vs. SGMT: 137%
Market capitalization -- EDIT: $394.7M vs. SGMT: $612.26M
EDIT [@Biotechnology] is valued at $394.7M. SGMT’s [@Biotechnology] market capitalization is $612.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green while SGMT’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • SGMT’s FA Score: 1 green, 4 red.
According to our system of comparison, SGMT is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while SGMT’s TA Score has 7 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 6 bearish.
  • SGMT’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, SGMT is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -12.50% price change this week, while SGMT (@Biotechnology) price change was +14.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 25, 2027.

SGMT is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

SGMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SGMT has been loosely correlated with VIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SGMT jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGMT
1D Price
Change %
SGMT100%
+4.78%
VIR - SGMT
45%
Loosely correlated
-0.15%
IMNM - SGMT
44%
Loosely correlated
+2.25%
TSHA - SGMT
41%
Loosely correlated
+0.12%
IMTX - SGMT
41%
Loosely correlated
+4.21%
EDIT - SGMT
41%
Loosely correlated
-4.99%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HNRG10.980.82
+8.07%
Hallador Energy Company
BRTX1.570.04
+2.61%
BioRestorative Therapies Inc
BPAC10.28N/A
N/A
Blueport Acquisition Ltd
IVZ28.63-0.24
-0.83%
Invesco Ltd
PLGO27.97-0.36
-1.27%
Pelagos Insurance Capital Limited